How Bourla was paid
$27.6M in total for fiscal 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Total |
|---|---|---|---|---|
| A. BourlaChairman and CEO | $1,800,000 | $5,400,000 | $18,000,000 | $27,585,301 |
| D. DentonCFO, EVP | $1,399,152 | $2,800,000 | $5,500,000 | $9,670,182 |
| C. BoshoffChief Scientific Officer and President, Research & Development | $1,400,000 | $3,150,000 | $6,600,000 | $10,006,039 |
| A. MalikChief U.S. Commercial Officer, EVP | $1,396,989 | $2,900,000 | $4,950,000 | $9,429,227 |
| D. LanklerChief Legal Officer, EVP | $1,422,142 | $2,675,000 | $4,950,000 | $9,106,276 |
What changed and why
- $27.6MChief Executive Officer Albert Bourla received a total compensation of $27,585,301 for fiscal 2025.
- $62.6BTotal revenues for full-year 2025 were $62.6 billion compared with $63.6 billion previously.
- 54.7%The say-on-pay advisory vote support dropped to 54.7% in 2025, prompting extensive shareholder engagement.
- $9.8BPfizer returned $9.8 billion to shareholders via quarterly dividends in 2025.
- $600MThe company achieved approximately $600 million in net cost savings through its manufacturing optimization program.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.